These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 37669348)

  • 21. Hepatitis C Virus Cascade of Care Among Perinatal Patients in Maine Diagnosed With Opioid Use Disorder, 2015-2020.
    Pfeiffer M; O'Connor A; Zimmerman C; Thakarar K; Ahrens K
    J Addict Med; 2023 May-Jun 01; 17(3):286-293. PubMed ID: 37267170
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pragmatic Experience with Risk-based versus Universal Hepatitis C Screening in Pregnancy: Detection of Infection and Postpartum Linkage to Care.
    Bushman ET; Subramani L; Sanjanwala A; Dionne-Odom J; Franco R; Owen J; Subramaniam A
    Am J Perinatol; 2021 Sep; 38(11):1109-1116. PubMed ID: 33934324
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Hepatitis Testing and Linkage-to-Care Data Review Process: An Approach to Ensuring the Quality of Program Data.
    Mezzo JL; Lamia TL; Danelski LL; Schipani AM; Stokes SA; Jacobs-Ware ED
    Public Health Rep; 2016; 131 Suppl 2(Suppl 2):44-8. PubMed ID: 27168661
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Modelling the impact of a national scale-up of interventions on hepatitis C virus transmission among people who inject drugs in Scotland.
    Fraser H; Mukandavire C; Martin NK; Goldberg D; Palmateer N; Munro A; Taylor A; Hickman M; Hutchinson S; Vickerman P
    Addiction; 2018 Nov; 113(11):2118-2131. PubMed ID: 29781207
    [TBL] [Abstract][Full Text] [Related]  

  • 25. NIH Consensus Statement on Management of Hepatitis C: 2002.
    NIH Consens State Sci Statements; 2002 Jun 10-12; 19(3):1-46. PubMed ID: 14768714
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment of Hepatitis C virus among people who inject drugs at a syringe service program during the COVID-19 response: The potential role of telehealth, medications for opioid use disorder and minimal demands on patients.
    Sivakumar A; Madden L; DiDomizio E; Eller A; Villanueva M; Altice FL
    Int J Drug Policy; 2022 Mar; 101():103570. PubMed ID: 34954493
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical effectiveness of pharmacist-led versus conventionally delivered antiviral treatment for hepatitis C virus in patients receiving opioid substitution therapy: a pragmatic, cluster-randomised trial.
    Radley A; de Bruin M; Inglis SK; Donnan PT; Hapca A; Barclay ST; Fraser A; Dillon JF
    Lancet Gastroenterol Hepatol; 2020 Sep; 5(9):809-818. PubMed ID: 32526210
    [TBL] [Abstract][Full Text] [Related]  

  • 28. HCV elimination in a Swiss opioid agonist therapy programme - a cohort study.
    Bregenzer A; Krismer C; Wendel S; Roser P; Fux CA
    Swiss Med Wkly; 2022 Dec; 152():40009. PubMed ID: 36509421
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost-effectiveness of syringe service programs, medications for opioid use disorder, and combination programs in hepatitis C harm reduction among opioid injection drug users: a public payer perspective using a decision tree.
    Ijioma SC; Pontinha VM; Holdford DA; Carroll NV
    J Manag Care Spec Pharm; 2021 Feb; 27(2):137-146. PubMed ID: 33506729
    [No Abstract]   [Full Text] [Related]  

  • 30. Implementation of a Collaborative HIV and Hepatitis C Screening Program in Appalachian Urgent Care Settings.
    Burrell CN; Sharon MJ; Davis SM; Wojcik EM; Martin IBK
    West J Emerg Med; 2018 Nov; 19(6):1057-1064. PubMed ID: 30429942
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of CDC Opioid-Prescribing Guidelines in a Community Hospital Emergency Department.
    Gumidyala L; Savul SA; Shofer FS; Green-McKenzie J
    J Public Health Manag Pract; 2021 May-Jun 01; 27(Suppl 3):S186-S190. PubMed ID: 33785694
    [TBL] [Abstract][Full Text] [Related]  

  • 32. M
    Martel-Laferrière V; Feaster DJ; Metsch LR; Schackman BR; Loignon C; Nosyk B; Tookes H; Behrends CN; Arruda N; Adigun O; Goyer ME; Kolber MA; Mary JF; Rodriguez AE; Yanez IG; Pan Y; Khemiri R; Gooden L; Sako A; Bruneau J
    Trials; 2022 Apr; 23(1):341. PubMed ID: 35461260
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Vital signs: evaluation of hepatitis C virus infection testing and reporting - eight U.S. sites, 2005-2011.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2013 May; 62(18):357-61. PubMed ID: 23657111
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prevalence, estimated incidence, risk behaviours, and genotypic distribution of hepatitis C virus among people who inject drugs accessing harm-reduction services in Kenya: a retrospective cohort study.
    Akiyama MJ; Cleland CM; Lizcano JA; Cherutich P; Kurth AE
    Lancet Infect Dis; 2019 Nov; 19(11):1255-1263. PubMed ID: 31540840
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Integrating Routine HCV Testing in Primary Care: Lessons Learned from Five Federally Qualified Health Centers in Philadelphia, Pennsylvania, 2012-2014.
    Coyle C; Kwakwa H; Viner K
    Public Health Rep; 2016; 131 Suppl 2(Suppl 2):65-73. PubMed ID: 27168664
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Recommendations for Providing Quality Sexually Transmitted Diseases Clinical Services, 2020.
    Barrow RY; Ahmed F; Bolan GA; Workowski KA
    MMWR Recomm Rep; 2020 Jan; 68(5):1-20. PubMed ID: 31899459
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prescribing Opioids for Chronic Pain: A Quality Improvement Project.
    Ajay G
    J Dr Nurs Pract; 2022 Sep; ():. PubMed ID: 36137749
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pediatric Hepatitis C Quality Improvement Project Improves Healthcare Access.
    Vallabhan MK; Castillo R; Roldan P; Rhoades N; Kong AS; Jimenez EY
    J Pediatr Gastroenterol Nutr; 2023 Mar; 76(3):371-378. PubMed ID: 36728827
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hepatitis C virus elimination in Swiss opioid agonist therapy programmes - the SAMMSU cohort.
    Bregenzer A; Bruggmann P; Castro E; Moriggia A; Rothen M; Thurnheer MC; Vernazza P; Scheidegger C
    Swiss Med Wkly; 2021 Mar; 151():w20460. PubMed ID: 33705563
    [TBL] [Abstract][Full Text] [Related]  

  • 40. High hepatitis C incidence in relation to prescription opioid injection and poly-drug use: Assessing barriers to hepatitis C prevention.
    Puzhko S; Roy É; Jutras-Aswad D; Artenie AA; Fortier E; Zang G; Bruneau J
    Int J Drug Policy; 2017 Sep; 47():61-68. PubMed ID: 28666636
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.